Evaxion Biotech Announces First Quarter 2022 Financial Results and Provides Business Update
Received regulatory clearance in Australia to initiate phase 2b trial of lead cancer therapy EVX-01 targeting melanomaCompleted recruitment for Phase 1/2a clinical trial for EVX-02 with all patients receiving